Skip to main content

Advertisement

SpringerLink
Log in

AMH and Its Clinical Implications

  • Mini Review Article
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

Abstract

Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male fetus. In women, AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation. As the size of the residual follicular pool depends on the quantity of small antral follicles and declines over time, the serum AMH level in women follows a characteristic trajectory: a gradual decline throughout the reproductive years and a precipitous drop at menopause, becoming undetectable soon after. Thus, AMH is clinically useful as a screening tool for diminished ovarian reserve (Cui et al. in Fertil Steril 105(02):481–485, 2016). Perturbations in serum AMH are linked with a variety of pathological conditions, for instance, polycystic ovaries syndrome (PCOS), the pathophysiology likely being the excess follicles in this syndrome which produce increased amounts of AMH (Dumont et al. in Reprod Biol Endocrinol 13:137, 2015). AMH is also elevated in some ovarian tumors such as adult granulosa cell tumors, and it can be used as a tumor marker to gauge response to therapy and monitor for recurrence. Within the domain of assisted reproductive technology, serum AMH assays are widely used to derive prognostic information such as the chance of successful ovarian stimulation, subsequent embryo quality and even pregnancy rates. Finally, in the rapidly evolving field of oncofertility, serum AMH holds great promise as a predictor of ovarian reserve after completion of cancer therapy. Our aim is to put forth an in-depth review of the clinical applications of AMH in contemporary practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cui L, Qin Y, Gao X, et al. Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertil Steril. 2016;105(02):481–5.

    Article  CAS  Google Scholar 

  2. Dumont A, Robin G, Catteau-Jonard S, et al. Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol. 2015;13:137.

    Article  CAS  Google Scholar 

  3. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(02):113–30.

    Article  CAS  Google Scholar 

  4. Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(06):698–710.

    Article  CAS  Google Scholar 

  5. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(02):129–40.

    Article  Google Scholar 

  6. Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011;26(9):2353–62.

    Article  CAS  Google Scholar 

  7. Tokura Y, Yoshino O, Ogura-Nose S, et al. The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment. J Assist Reprod Genet. 2013;30(6):821–5.

    Article  Google Scholar 

  8. Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones. 2011;10(2):95–103.

    Article  Google Scholar 

  9. Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014;12:26.

    Article  CAS  Google Scholar 

  10. Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment anti-Müllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99:477–83.

    Article  CAS  Google Scholar 

  11. Dunlop CE, Anderson RA. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas. 2015;80:245–50.

    Article  CAS  Google Scholar 

  12. Decanter C, Cloquet M, Dassonneville A, et al. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. Reprod Biomed Online. 2018;36:711–8.

    Article  CAS  Google Scholar 

  13. Cobo A, Garcia-Velasco JA, Coello A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105:755–64.

    Article  Google Scholar 

  14. Sermondade N, Sonigo C, Sifer C, et al. Serum anti-Müllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation. Fertil Steril. 2019;111:357–62.

    Article  CAS  Google Scholar 

  15. Fabbri R, Macciocca M, Melotti C, et al. Anti-Müllerian hormone as an ovarian reserve marker in young cancer women who undergo ovarian tissue cryopreservation. Future Oncol. 2014;10:1343–51.

    Article  CAS  Google Scholar 

  16. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–44.

    Article  CAS  Google Scholar 

  17. L. Kalich-Philosoph, H. Roness, A. Carmely et al., “Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility,” Science Translational Medicine, vol. 5, no. 185, Article ID 185ra62, 2013.

  18. Roness H, Spector I, Leichtmann-Bardoogo Y, et al. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet. 2019;36:1793–803.

    Article  CAS  Google Scholar 

  19. Färkkilä A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors—a comparative study with inhibin B. Int J Cancer. 2015;137:1661–71.

    Article  CAS  Google Scholar 

  20. Zhang T, Deng L, Xiong Q, et al. Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor. Oncol Lett. 2018;16(3):3260–6.

    PubMed  PubMed Central  Google Scholar 

  21. Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. Hum Reprod. 2014;29(4):791–801.

    Article  CAS  Google Scholar 

  22. Bungum L, Franssohn F, Bungum M, et al. The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women. PLoS ONE. 2013;8(9), Article ID e68223

  23. Lindhardt Johansen M, Hagen CP, Johannsen TH, et al. Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013;2013, Article ID 198698

  24. Josso N, Rey RA, Picard JY. Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol. 2013;2013:674105.

    Article  CAS  Google Scholar 

  25. Aksglaede L, Christiansen P, Sørensen K, et al. Serum concentrations of anti-Müllerian hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. Acta Paediatr Int J Paediatr. 2011;100(6):839–45.

    Article  CAS  Google Scholar 

  26. Visser JA, Hokken-Koelega ACS, Zandwijken GRJ, et al. Anti-Mullerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. Hum Reprod. 2013;28(7):1899–907.

    Article  CAS  Google Scholar 

  27. Bertone-Johnson ER, Manson JE, Purdue-Smithe AC, et al. Anti-Mullerian hormone levels and incidence of early natural menopause in a prospective study. Hum Reprod. 2018;33:1175–82.

    Article  Google Scholar 

  28. Depmann M, Eijkemans MJ, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta-analysis. J Clin Endocrinol Metab. 2018;103:3593–600.

    Article  Google Scholar 

  29. Gleicher N, Barad DH. Dehydroepisterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011;9:67.

    Article  CAS  Google Scholar 

  30. Sing V, Thakur P, Agrawal S, et al. Role of DHEA in diminished ovarian reserve, systematic review. World J Pharmaceut Res. 2015;4:2488–507.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, 34/2 Abhyankar Road, Dhantoli, Nagpur, Maharashtra, 440012, India

    Laxmi Shrikhande, Bhushan Shrikhande & Aditya Shrikhande

Authors
  1. Laxmi Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhushan Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aditya Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laxmi Shrikhande.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Laxmi Shrikhande is a Medical Director and Senior Consultant at Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, India. Bhushan Shrikhande is a Clinical Associate at Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, India. Aditya Shrikhande is a Research Associate at Shrikhande Hospital and Research Centre Pvt Ltd, Nagpur, India.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shrikhande, L., Shrikhande, B. & Shrikhande, A. AMH and Its Clinical Implications. J Obstet Gynecol India 70, 337–341 (2020). https://doi.org/10.1007/s13224-020-01362-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13224-020-01362-0

Keywords

Search

Navigation